Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Stephanie Smith-Marrone"'
Autor:
Charles M. Rudin, Piro Lito, Lee M. Krug, Camelia S. Sima, Stephanie Smith-Marrone, Natasha Rekhtman, Inderpal S. Sarkaria, Maria Laureana Santos-Zabala, William D. Travis, Gregory J. Riely, Tunc Iyriboz, Afsheen Iqbal, Jarushka Naidoo, John J. Fiore, Maria Catherine Pietanza, Stephen Veach, Kaitlin M. Woo, Mark G. Kris
Publikováno v:
Clinical Lung Cancer. 17:e121-e129
Background Large cell neuroendocrine carcinoma (LCNEC) accounts for approximately 3% of lung cancers. Pathologic classification and optimal therapies are debated. We report the clinicopathologic features, treatment and survival of a series of patient
Autor:
Jennifer M. McNiff, Abigail Waldman, Stephanie Smith-Marrone, William S. Asch, AnnMarie Liapakis, Oscar R. Colegio
Publikováno v:
JAAD Case Reports
Solid organ transplant recipients (SOTR) suffer an overall 2-fold increased risk of any malignancy compared with the general population. Multiple strategies exist to address this risk in these patients. Revision of immunosuppression is the cornerston
Autor:
Daphna Y. Gelblum, David G. Pfister, Nancy Y. Lee, R.M. Gewanter, Han Xiao, Brynna Lipson, Shrujal S. Baxi, Jatin P. Shah, Eric J. Sherman, Heiko Schöder, Lisa Cox, Nora Katabi, Stephanie Smith-Marrone, Rachel Kurtzman, Matthew G. Fury, Sofia Haque, Karen D. Schupak
Publikováno v:
Head & Neck. 38:E566-E570
Background The purpose of this study was to evaluate the efficacy and tolerability of the addition of 2 monoclonal antibodies, bevacizumab and cetuximab, to 2 cycles of high-dose cisplatin administered concurrently with intensity-modulated radiation
Autor:
Stephanie Smith-Marrone, Lauren J. Rogak, John J. Fiore, Samantha Kass Newman, Maria Catherine Pietanza, Ethan Basch, Patrick Hilden, Marwan Shouery, Michelle S. Ginsberg, Mary Shaw, Lawrence H. Schwartz, Mark G. Kris, Alex E. Lash, Matthew D. Hellmann
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 11(6)
Introduction Many patients with lung cancers cannot receive platinum-containing regimens owing to comorbid medical conditions. We designed the PPB (paclitaxel, pemetrexed, and bevacizumab) regimen to maintain or improve outcomes while averting the un
Autor:
Susana Hernandez, Naiyer A. Rizvi, Matthew Bacchetta, Tiffany Negri, Anjali Saqi, Stephanie Smith-Marrone, Codruta Chiuzan, Vijeta Patel, Mark B. Stoopler, Joshua R. Sonett, Justin F. Gainor, Adrian G. Sacher, Claud Grigg, Frank D'Ovidio, Mark M. Awad, Robert Garofano, Catherine A. Shu
Publikováno v:
Journal of Clinical Oncology. 36:8532-8532
8532Background: Neoadjuvant chemotherapy is an accepted treatment approach for resectable NSCLC. Major pathologic response (mPR) defined as ≥ 90% tumor necrosis is seen in 20% of patients (pts) rec...
Autor:
Matthew G, Fury, Han, Xiao, Eric J, Sherman, Shrujal, Baxi, Stephanie, Smith-Marrone, Karen, Schupak, Richard, Gewanter, Daphna, Gelblum, Sofia, Haque, Heiko, Schoder, Jatin P, Shah, Nora, Katabi, Rachel, Kurtzman, Brynna, Lipson, Lisa, Cox, Nancy Y, Lee, David G, Pfister
Publikováno v:
Headneck. 38
The purpose of this study was to evaluate the efficacy and tolerability of the addition of 2 monoclonal antibodies, bevacizumab and cetuximab, to 2 cycles of high-dose cisplatin administered concurrently with intensity-modulated radiation therapy (IM
Autor:
J. L. Lee, Matthew G. Fury, Boris Mueller, Sofia Haque, Sarah Kurz, David G. Pfister, Nancy Y. Lee, Daphna Y. Gelblum, Eric J. Sherman, P.R. Dutta, Ronglai Shen, Suzanne L Wolden, Shyam Rao, Kenneth K.-S. Ng, Nora Katabi, Stephanie Smith-Marrone
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology, vol 25, iss 3
BackgroundThere is a clinical need to improve the efficacy of standard cetuximab + concurrent intensity-modulated radiation therapy (IMRT) for patients with locally and/or regionally advanced HNSCC. Taxanes have radiosensitizing activity against HNSC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c7a6fad02d2ca24d9a25d94f61ae46d
https://europepmc.org/articles/PMC4433511/
https://europepmc.org/articles/PMC4433511/
Autor:
Kenneth K.-S. Ng, Matthew G. Fury, Sofia Haque, Kenneth M. Algazy, Neeraj Agarwal, Sandeep K. Rajan, Susan H. Korte, Donna Lisa, Tawee Tanvetyanon, Eric J. Sherman, Han Xiao, Stephanie Smith-Marrone, David G. Pfister, Furhan Yunus, Corey J. Langer, Brynna Lipson, Dean Lim, Ranee Mehra, Bruce Brockstein
Publikováno v:
Memorial Sloan Kettering Cancer Center
Scopus-Elsevier
Scopus-Elsevier
Cetuximab is typically administered on a weekly schedule for patients with recurrent or metastatic head and neck squamous cell cancer (HNSCC). This study explores cetuximab administered every 2 weeks (q2w). In this multicenter randomized prospective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a165f1ccaf5ea7cdc6a9b0cf15a388e3
https://europepmc.org/articles/PMC5726232/
https://europepmc.org/articles/PMC5726232/
Autor:
Dennis Stephens, Michelle S. Ginsberg, Helena Alexandra Yu, Stephanie Smith-Marrone, Mark G. Kris, Camelia S. Sima, John J. Fiore, Gregory J. Riely, Maria Catherine Pietanza, Melissa Goldstein
Publikováno v:
Journal of Clinical Oncology. 33:8064-8064
8064 Background: Patients with ALK + non-small cell lung cancer (NSCLC) initially respond to crizotinib, but eventually develop resistance. Treatment of patients with ALK positive lung cancer with HSP90 inhibitors leads to clinical and radiographic r
Autor:
A. Iqbal, Inderpal S. Sarkaria, Charles M. Rudin, Lee M. Krug, Natasha Rekhtman, Maria Laureana Santos-Zabala, Kaitlin M. Woo, Mark G. Kris, Jarushka Naidoo, G. J. Riely, Tunc Iyriboz, C.S. Sima, Stephanie Smith-Marrone, S.R. Veach, John J. Fiore, Maria Catherine Pietanza
Publikováno v:
Annals of Oncology. 25:iv398
Aim: LCNEC is a rare thoracic malignancy, for which pathologic classification and optimal therapies are debated. We report the largest series of stage IV LCNECs, evaluating clinicopathologic features, treatment and survival. Methods: Pts with stage I